Navigating FDA Guidelines in Obesity Drug Development

This chapter examines the recent FDA guidance updates on obesity drug development, emphasizing the unchanged focus on percentage weight loss and raised concerns for companies like Viking Therapeutics. Additionally, it highlights the growing interest in obesity biotech startups, such as Verdeva's substantial funding round, and explores implications for innovation within the sector.